- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 25.04. | DIAGONAL BIO AB: Diagonal Bio announces change of news plattform | 1 | Cision News | ||
| 28.03. | DIAGONAL BIO AB: Diagonal Bio publishes Year-End Report for 2024 | 1 | Cision News | ||
| 21.03. | DIAGONAL BIO AB: Diagonal Bio granted patent in Japan | 1 | Cision News | ||
| 19.03. | Nomination Committee change in Diagonal Bio AB (publ.) | 1 | Cision News | ||
| DIAGONAL BIO Aktie jetzt für 0€ handeln | |||||
| 19.03. | DIAGONAL BIO AB: Trading in Diagonal Bio's shares and warrants of series TO 2 on NGM Nordic SME begins today | 1 | Cision News | ||
| 18.03. | NGM MARKET NOTICE: #25-27 Warrants issued by Diagonal Bio AB approved for listing at NGM | 2 | Cision News | ||
| 14.03. | NGM MARKET NOTICE: #25-23 Diagonal Bio AB approved for listing at NGM | 1 | Cision News | ||
| 13.03. | DIAGONAL BIO AB: Stall Courant and Diagonal Bio agree to a pilot test of LAMPlify® | 1 | Cision News | ||
| 04.03. | Diagonal Bio AB: Diagonal Bio has been approved for delisting from Nasdaq First North Growth Market | 223 | GlobeNewswire (Europe) | Diagonal Bio AB (publ) ("Diagonal Bio" or "the Company") today announces that Nasdaq has approved Diagonal Bio's application for delisting from Nasdaq First North Growth Market ("First North"). The... ► Artikel lesen | |
| 04.03. | Diagonal Bio AB: Diagonal Bio has received conditional approval for listing on NGM Nordic SME | 195 | GlobeNewswire (Europe) | Diagonal Bio AB (publ) ("Diagonal Bio" or "the Company") has received conditional approval for listing on NGM Nordic SME ("NGM"). The first day of trading is planned for 19 March 2025. This means that... ► Artikel lesen | |
| 03.03. | DIAGONAL BIO AB: Diagonal Bio applies for change of marketplace to NGM Nordic SME | 1 | Cision News | ||
| 19.02. | Diagonal Bio AB's announces last day of trading in BTU and first day of trading in warrants of series TO 2 | 2 | Cision News | ||
| 18.02. | Diagonal Bio AB resolves on a directed issue of units to all external underwriters | 4 | Cision News | ||
| 12.02. | DIAGONAL BIO AB: Diagonal Bio's CEO Karin Wehlin increases ownership | 1 | Cision News | ||
| 07.02. | Diagonal Bio AB: Diagonal Bio AB's rights issue of units oversubscribed | 349 | GlobeNewswire (Europe) | The subscription period in Diagonal Bio AB's ("Diagonal Bio" or the "Company") rights issue of units of initially approximately SEK 6.0 million ended on 6 February 2025 (the "Rights Issue"). The Rights... ► Artikel lesen | |
| 05.02. | DIAGONAL BIO AB: Stall Goop conducts pilot test of LAMPlify® | 1 | Cision News | ||
| 29.01. | Diagonal Bio AB: Diagonal Bio announces positive pilot test results and secures order from StallZet | 123 | GlobeNewswire (Europe) | Diagonal Bio AB (publ) ("Diagonal Bio" or the "Company") announces an order valued at approximately SEK 150,000 from Daniel Redén, a renowned horse trainer at StallZet. The order comes as a result of... ► Artikel lesen | |
| 22.01. | Diagonal Bio AB: Diagonal Bio AB publishes investment memorandum prior to upcoming rights issue of units | 208 | GlobeNewswire (Europe) | The subscription period of Diagonal Bio AB's ("Diagonal Bio" or the "Company") rights issue of units, which was resolved on 23 December 2024 by the Board of Directors together with the resolution on... ► Artikel lesen | |
| 17.01. | XFRA CAPITAL ADJUSTMENT INFORMATION - 17.01.2025 | 749 | Xetra Newsboard | Das Instrument 2DV0 FR001400SVN0 DRONE VOLT SACA EO 1 EQUITY wird ex Kapitalmassnahme gehandelt am 17.01.2025 The instrument 2DV0 FR001400SVN0 DRONE VOLT SACA EO 1 EQUITY is traded ex capital adjustment... ► Artikel lesen | |
| 11.11.24 | Nasdaq Stockholm AB: Diagonal Bio AB receives observation status | 271 | GlobeNewswire | Today, on November 11, 2024, Diagonal Bio AB (the "Company") disclosed a press
release with information on the Company's financial situation.
The rules of Nasdaq First North Growth Market state that... ► Artikel lesen |
20 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| INTELLIA THERAPEUTICS | 11,505 | +1,77 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | CAMBRIDGE, Mass., July 07, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies... ► Artikel lesen | |
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,396 | -1,63 % | PacBio HiFi Sequencing Powers First Arab Human Pangenome, Published in Nature Communications | ||
| CENTOGENE | 0,120 | +15,38 % | Research and Markets: Europe Hereditary Genetic Testing Market Research 2024-2033, Competitive Analysis of Centogene, Eurofins Scientific, and F. Hoffmann-La Roche - ResearchAndMarkets.com | The "Europe Hereditary Genetic Testing Market: Focus on Genetic Testing Type and Country Analysis and Forecast, 2024-2033" report has been added to ResearchAndMarkets.com's offering.
The Europe... ► Artikel lesen | |
| ATAI LIFE SCIENCES | 2,981 | +3,90 % | Atai backs away from schizophrenia drug after trial failure | ||
| BIOMERIEUX | 126,80 | +1,52 % | Dividendenbekanntmachungen (09.06.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ALLSTATE CORPORATION US0200021014 1 USD 0,8776 EUR ALPHABET INC CL A US02079K3059 0,21 USD 0,1842 EUR ALPHABET INC CL C US02079K1079 0... ► Artikel lesen | |
| CYCLACEL | 13,036 | -4,71 % | Cyclacel Pharmaceuticals, Inc. - 8-K, Current Report | ||
| SYROS PHARMACEUTICALS | 0,108 | -100,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 25.03.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 25.03.2025.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 25.03.2025.ISIN NameCA05553A1075 THE... ► Artikel lesen | |
| GENUS | 28,400 | 0,00 % | Genus: Underlying Group Trading In-line With Expectations | LONDON (dpa-AFX) - Genus (GNS.L) issued trading update for fiscal year ended 30 June 2025. The Group said it recorded strong underlying Group trading in-line with expectations. As a result of... ► Artikel lesen | |
| ANAPTYSBIO | 23,200 | +0,87 % | Analyst Expectations For AnaptysBio's Future | ||
| ABIONYX PHARMA | 1,440 | -1,37 % | ABIONYX Pharma: Monthly Statement of Total Voting Rights and Shares Forming the Company's Share Capital | Article L233-8-II of the French Commercial Code Article 223-16 of the General Regulations of the AMF (French Financial Markets Authority)
Regulatory News:
ABIONYX Pharma (Paris:ABNX)
Market:... ► Artikel lesen | |
| XTL BIOPHARMACEUTICALS | 1,400 | +2,19 % | XTL BIOPHARMACEUTICALS LTD - 6-K, Report of foreign issuer | ||
| AKESO | 16,800 | +1,82 % | Akeso, Inc.: NMPA Accepts sNDA for Ivonescimab in Combination with Chemotherapy as First-Line Treatment for Advanced Squamous Non-Small Cell Lung Cancer | HONG KONG, July 28, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is pleased to announce that the National Medical Products Administration... ► Artikel lesen | |
| MEIRAGTX | 7,100 | 0,00 % | MeiraGTx Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for AAV-GAD for the Treatment of Parkinson's Disease | - This RMAT designation is based on data from 3 clinical studies demonstrating the potential benefit of AAV-GAD as a one-time treatment for Parkinson's disease - RMAT designation includes the benefits... ► Artikel lesen | |
| MAAT PHARMA | 5,140 | +11,50 % | MaaT Pharma Secures €37.5 Million Loan From European Investment Bank (EIB) Marking a New Step in Advancing its Clinical Program in Hemato-Oncology | Tranche-based financing to support clinical development for the Company's late-stage assets in hemato-oncology including Xervyteg currently under review for potential approval by the EMA and MaaT033... ► Artikel lesen | |
| ISOFOL MEDICAL | 0,069 | -6,59 % | Isofol Medical AB: Isofol successfully completes pre-IND meeting with the FDA for arfolitixorin | GOTHENBURG, Sweden, July 16, 2025 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces today that the company has successfully completed a pre-IND meeting with the U.S. Food and Drug Administration... ► Artikel lesen |
Das Unternehmen DIAGONAL BIO AB kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 0,000 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu DIAGONAL BIO AB finden Sie auf Wallstreet Online.